Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2010-08-22 / Cancer Biol. Ther. 2010 Aug;10(4):368-75The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2010-08-13 / Vaccine 2010 Oct;28(42):6891-900Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs
/in International Publications, Micronutrients /von 2010-08-08 / Cancer Chemother. Pharmacol. 2011 May;67(5):1157-66Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway
/in Hyperthermia, International Publications, Newcastle Disease Virus, Pancreatic Cancer /von 2010-08-01 / Surgery 2010 Aug;148(2):325-34[Anti-tumor immunity of Newcastle disease virus HN protein is influenced by differential subcellular targeting]
/in International Publications, Newcastle Disease Virus /von 2010-08-01 / Zhongguo Fei Ai Za Zhi 2010 Aug;13(8):773-6[Progress in using Newcastle disease virus for tumor therapy: a review]
/in International Publications, Newcastle Disease Virus /von 2010-08-01 / Sheng Wu Gong Cheng Xue Bao 2010 Aug;26(8):1031-6Prostate cancer as a model for tumour immunotherapy
/in Dendritic Cells, International Publications, Prostate Cancer /von 2010-08-01 / Nat. Rev. Immunol. 2010 Aug;10(8):580-93[Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer]
/in Dendritic Cells, International Publications, Prostate Cancer /von 2010-08-01 / Zhonghua Nan Ke Xue 2010 Aug;16(8):698-704Global sensitivity analysis and model-based reactive scheduling of targeted cancer immunotherapy
/in Dendritic Cells, International Publications /von 2010-08-01 / BioSystems 2010 Aug;101(2):117-26
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution